Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
Earnings Data
Report Date
Mar 11, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.49Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Mirum Pharmaceuticals had a strong third quarter with significant revenue growth and positive net income for the first time. The company continues to advance its clinical pipeline and expand internationally. However, there are some challenges in revenue consistency and the adoption of genetic testing in certain segments.Company Guidance
Strong Revenue Growth
Mirum Pharmaceuticals reported third quarter revenue of $133 million, representing a nearly 50% year-over-year increase, driven by the performance of LIVMARLI and their bile acid portfolio.
Positive Financial Milestone
The company recognized positive net income for the first time, highlighting the operating leverage in their commercial model.
Successful International Expansion
LIVMARLI net product sales totaled $92 million, with $28 million from international markets, supported by expanding reimbursement and launches in new geographies.
Advancement in Clinical Pipeline
Enrollment completed for the Phase IIb VISTAS study in PSC, with top line data expected in Q2 2026. The company is optimistic about volixibat's potential to become the first approved treatment in this setting.
Increased Cash Reserves
Mirum's cash, cash equivalents, and investments increased by $85 million from the beginning of the year, reaching $378 million.
MIRM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MIRM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 04, 2025 | $70.97 | $70.09 | -1.24% |
Aug 06, 2025 | $53.39 | $59.82 | +12.04% |
May 07, 2025 | $41.22 | $45.24 | +9.75% |
Feb 26, 2025 | $50.52 | $46.98 | -7.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Mirum Pharmaceuticals Inc (MIRM) report earnings?
Mirum Pharmaceuticals Inc (MIRM) is schdueled to report earning on Mar 11, 2026, After Close (Confirmed).
What is Mirum Pharmaceuticals Inc (MIRM) earnings time?
Mirum Pharmaceuticals Inc (MIRM) earnings time is at Mar 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MIRM EPS forecast?
MIRM EPS forecast for the fiscal quarter 2025 (Q4) is -0.05.